» Articles » PMID: 37420040

MiR-1-3p Inhibits Osteosarcoma Cell Proliferation and Cell Cycle Progression While Promoting Cell Apoptosis by Targeting CDK14 to Inactivate Wnt/Beta-Catenin Signaling

Overview
Journal Mol Biotechnol
Publisher Springer
Date 2023 Jul 7
PMID 37420040
Authors
Affiliations
Soon will be listed here.
Abstract

Osteosarcoma (OS) is a common bone malignancy and is diagnosed frequently in children and young adults. According to previous RNA sequencing, miR-1-3p is downregulated in OS clinical samples. Nevertheless, the functions of miR-1-3p in OS cell process and the related mechanism have not been revealed yet. In the current study, miR-1-3p expression in OS tissues and cells were evaluated using quantitative polymerase chain reaction. CCK-8 assays were conducted to measure OS cell viability in response to miR-1-3p overexpression. Colony forming assays and EdU staining were conducted for measurement of cell proliferation, and flow cytometry analysis was performed to determine cell apoptosis and cell cycle progression. Protein levels of apoptotic markers, beta-catenin, and Wnt downstream targets were quantified using western blotting. The binding relation between miR-1-3p and cyclin dependent kinase 14 (CDK14) was validated utilizing luciferase reporter assays. Experimental results revealed that miR-1-3p expression was decreased in OS tissues and cells. Additionally, miR-1-3p inhibited cell proliferation and cell cycle progression while enhancing OS cell apoptosis. Moreover, miR-1-3p directly targeted CDK14 and inversely regulated CDK14 expression in OS cells. Furthermore, miR-1-3p inactivated the Wnt/beta-catenin signaling. CDK14 overexpression partially rescued the inhibitory impact of miR-1-3p on OS cell growth. Overall, miR-1-3p inhibits OS cell proliferation and cell cycle progression while promoting cell apoptosis by targeting CDK14 and inactivating the Wnt/beta-catenin signaling.

Citing Articles

Wnt/β-catenin signaling pathway: an attractive potential therapeutic target in osteosarcoma.

Ding Y, Chen Q Front Oncol. 2025; 14:1456959.

PMID: 40028002 PMC: 11867957. DOI: 10.3389/fonc.2024.1456959.


The important role of miR-1-3p in cancers.

Dai S, Li F, Xu S, Hu J, Gao L J Transl Med. 2023; 21(1):769.

PMID: 37907984 PMC: 10617136. DOI: 10.1186/s12967-023-04649-8.

References
1.
Corre I, Verrecchia F, Crenn V, Redini F, Trichet V . The Osteosarcoma Microenvironment: A Complex But Targetable Ecosystem. Cells. 2020; 9(4). PMC: 7226971. DOI: 10.3390/cells9040976. View

2.
Chen C, Xie L, Ren T, Huang Y, Xu J, Guo W . Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. Cancer Lett. 2020; 500:1-10. DOI: 10.1016/j.canlet.2020.12.024. View

3.
Gaspar N, Occean B, Pacquement H, Bompas E, Bouvier C, Brisse H . Results of methotrexate-etoposide-ifosfamide based regimen (M-EI) in osteosarcoma patients included in the French OS2006/sarcome-09 study. Eur J Cancer. 2017; 88:57-66. DOI: 10.1016/j.ejca.2017.09.036. View

4.
Vishnoi A, Rani S . miRNA Biogenesis and Regulation of Diseases: An Updated Overview. Methods Mol Biol. 2022; 2595:1-12. DOI: 10.1007/978-1-0716-2823-2_1. View

5.
Doghish A, Hegazy M, Ismail A, El-Mahdy H, Elsakka E, Elkhawaga S . A spotlight on the interplay of signaling pathways and the role of miRNAs in osteosarcoma pathogenesis and therapeutic resistance. Pathol Res Pract. 2023; 245:154442. DOI: 10.1016/j.prp.2023.154442. View